CymaBay Therapeutics

OverviewSuggest Edit

CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. The Company's two key clinical development candidates are Seladelpar and Arhalofenate. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and the epidemic in nonalcoholic SteatoHepatitis. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. The Company's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

TypePublic
Founded1991
HQNewark, CA, US
Websitecymabay.com

Latest Updates

Employees (est.) (Mar 2020)24(-33%)
Job Openings11
Revenue (FY, 2013)$0
Share Price (Sept 2021)$3.9(+2%)
Cybersecurity ratingCMore

Key People/Management at CymaBay Therapeutics

Sujal Shah

Sujal Shah

President and Chief Executive Officer, Director
Robert J. Wills

Robert J. Wills

Chairman
Klara Dickinson

Klara Dickinson

Chief Regulatory and Quality Assurance Officer
Janet Dorling

Janet Dorling

Director
Dennis Kim

Dennis Kim

Chief Medical Officer
Caroline Loewy

Caroline Loewy

Director
Show more

CymaBay Therapeutics Office Locations

CymaBay Therapeutics has an office in Newark
Newark, CA, US (HQ)
7575 Gateway Blvd #110
Show all (1)

CymaBay Therapeutics Financials and Metrics

CymaBay Therapeutics Revenue

USD

Net income (Q1, 2021)

(17.6m)

EBIT (Q1, 2021)

(17.6m)

Market capitalization (9-Sept-2021)

269.8m

Closing stock price (9-Sept-2021)

3.9

Cash (31-Mar-2021)

43.3m

EV

228.1m
CymaBay Therapeutics's current market capitalization is $269.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

4.9m8.2m8.9m9.6m12.4m14.4m19.2m17.4m

R&D expense

4.5m15.8m17.0m15.9m18.9m58.1m83.8m35.9m

Operating expense total

9.4m24.0m25.9m25.6m31.3m72.5m103.1m53.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.4m11.6m7.7m10.5m23.1m49.0m24.9m28.2m

Accounts Receivable

110.0k211.0k5.0m

Prepaid Expenses

364.0k2.0m1.1m1.4m1.2m2.6m1.4m2.8m

Current Assets

32.2m37.2m42.8m18.5m103.5m181.6m202.9m151.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

32.1m22.3m8.0m16.4m10.8m11.7m6.7m21.2m12.4m6.8m13.7m9.5m23.0m65.6m44.7m41.8m125.6m28.1m43.5m56.8m96.1m47.3m43.3m

Accounts Receivable

168.0k10.0k14.0k17.0k

Prepaid Expenses

33.0k1.9m1.5m1.4m1.4m996.0k1.5m1.1m1.0m1.3m1.1m1.1m1.4m1.4m2.1m1.8m4.8m7.9m768.0k1.4m974.0k820.0k1.9m

Current Assets

32.1m30.9m25.4m44.4m34.5m28.3m48.6m36.5m30.2m24.5m24.6m17.9m103.7m231.2m216.7m202.3m270.1m249.8m227.8m185.9m174.1m166.1m133.3m
USDQ3, 2013

Financial Leverage

1.6 x
Show all financial metrics

CymaBay Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

CymaBay Therapeutics Online and Social Media Presence

Embed Graph

CymaBay Therapeutics News and Updates

CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webc…

CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021

NEWARK, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivere…

CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

NEWARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webca…

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021

NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio web…

CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference

NEWARK, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be delivered du…

CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leerink 10t…
Show more

CymaBay Therapeutics Blogs

CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 months Results highlight the potential for seladelpar to offer patients an efficacious and safe second line treatment option Global 52-week Phase 3 registration study (RESPONSE) to begin enrol…

CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes

The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase secretion of glucagon, a hormone that reverses low blood glucose levels (hypoglycemia) in individuals …

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

NEWARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation highligh…

CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webc…

CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020

Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosis Self-reported pruritus improved at one year for patients in highest categories of baseline itch Selected for inclusion in the “Best of ILC” presentation Results mirror recently reported ENHANCE…

CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020

A featured presentation will highlight final results from a 1-year, open-label Phase 2 study of seladelpar in primary biliary cholangitis (PBC) NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and provid…
Show more

CymaBay Therapeutics Frequently Asked Questions

  • When was CymaBay Therapeutics founded?

    CymaBay Therapeutics was founded in 1991.

  • Who are CymaBay Therapeutics key executives?

    CymaBay Therapeutics's key executives are Sujal Shah, Robert J. Wills and Klara Dickinson.

  • How many employees does CymaBay Therapeutics have?

    CymaBay Therapeutics has 24 employees.

  • Who are CymaBay Therapeutics competitors?

    Competitors of CymaBay Therapeutics include EMS Pharma, Livzon Pharmaceutical Group and PPD.

  • Where is CymaBay Therapeutics headquarters?

    CymaBay Therapeutics headquarters is located at 7575 Gateway Blvd #110, Newark.

  • Where are CymaBay Therapeutics offices?

    CymaBay Therapeutics has an office in Newark.

  • How many offices does CymaBay Therapeutics have?

    CymaBay Therapeutics has 1 office.